Chongqing Genrix Biopharmaceutical Co Ltd

688443

Company Profile

  • Business description

    Chongqing Genrix Biopharmaceutical Co Ltd is engaged in the research & development, production and sales of antibody drugs. The company has a total of more than ten products under research covering three major therapeutic areas. The progress of core products is leading, and some product pipelines are as follows; autoimmune disease, infectious disease, and tumor. Its product Xeligekimab injection (Xeligekimab) is a recombinant fully human anti-IL-17A monoclonal antibody independently developed by the company, which has been accepted by the National Medical Products Administration (NMPA) for new drug marketing applications.

  • Contact

    No. 699, Maliu Avenue
    Area A, Building 2
    International Bio City
    Banan
    Chongqing401338
    CHN

    T: +86 2361758666

    http://www.genrixbio.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Biotechnology

    Fiscal Year End

    31 December 2025

    Employees

    743

Stocks News & Analysis

stocks

What does big US court decision mean for Google’s parent company Alphabet?

Alphabet shares popped 7% after the ruling on September 2 and have now rallied by around 50% since April.
stocks

Our only 5-star wide moat ASX share

A difficult year but better times ahead.
stocks

Is this still an ASX share to own forever?

Find out how this defensive player has fared after earnings.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries9,140.5011.000.12%
CAC 407,674.7824.14-0.31%
DAX 4023,596.98173.35-0.73%
Dow JONES (US)45,400.86220.43-0.48%
FTSE 1009,208.218.66-0.09%
HKSE25,417.98359.471.43%
NASDAQ21,700.397.30-0.03%
Nikkei 22543,018.75438.481.03%
NZX 50 Index13,223.5390.330.69%
S&P 5006,481.5020.58-0.32%
S&P/ASX 2008,871.208.600.10%
SSE Composite Index3,812.5146.641.24%

Market Movers